Siglec-5 Protein, Cynomolgus (HEK293, His)

Siglec-5 Protein is a member of the sialic acid-binding immunoglobulin-like lectin (Siglec) family. Siglec-5 is a member of the CD33-related subset of Siglecs and is expressed on myeloid cells of the hemopoietic system. Siglec-5 inhibits the response of innate immune cells, such as monocytes and neutrophils against pathogens. Siglec-5 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived Siglec-5 protein, expressed by HEK293 , with C-6*His labeled tag.

Sialic acid-binding immunoglobulin-like lectin 5 (Siglec-5) is a member of the sialic acid-binding immunoglobulin-like lectin (Siglec) family. Siglec-5 is a member of the CD33-related subset of Siglecs and is expressed on myeloid cells of the hemopoietic system. Siglec-5 inhibits the response of innate immune cells, such as monocytes and neutrophils against pathogens. Overexpression of Siglec-5 inhibits the activity of T cell receptor (TCR)-induced transcription factors. In addition, binding of Siglec-5 to the GBS β-protein reduces primary T cell activation and leads to decreased production of cytokines and surface antigens. A soluble form of Siglec-5 enhances cytokine production and cytotoxic granule release by cancer antigen-specific T cells. Siglec-5 is an inhibitory receptor with the potential to mediate SHP-1 and/or SHP-2-dependent signaling in the absence of tyrosine phosphorylation. Plasma Siglec-5 can be used as a diagnostic marker for critical Limb Ischemia and fulminant myocarditis^[1][2][3][4].

Cynomolgus

HEK293

C-6*His

A0A0B4J1D1 (E17-G435)

/

Partial

EEPGYELQVQKSVTVQEGLCVLVPCSFSYPWNSWYSPSPLYVYWFRDGESQYYAEAVATNNPDRRVKPETQGRFRLLGDVRNKNCSLSIGDARMGDTGNYYFRVERGRNVKYNYVQNKLNLEVTALTEKPDVRFLEPLESGRLTRLSCSLPGSCEVGRPLTFSWTGDVLSPLDPETTGSSELTLTPRPEDHGTNLTCHVKHQGAQVTTERTVQLNVSYAPQNITIFRNGTALEILQNTSTLLVLEGEALRLLCEAPSNPPAHLSWFQASSAPNTTPIANTGILELPRVEFTKEGVFTCRAQHPLGSLHIFLNLSVYSLPQLLGPSCSWEAESLHCSCSFRAWPAPSLCWWLGEKPLEGNSSQGSFKVNSSSAGPWANSSLILHGGLTSVLKVSCKGWNTYGSQSGSVVLLQGRLNLRTG

Approximately 90 kDa,based on SDS-PAGE under reducing conditions.

≥ 90%, as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.